Dr. Morito Kurata is currently an Associate Professor at the Division of Integrated Facilities, Pathology of Tokyo Medical and Dental University, Japan. He graduated from the Faculty of Medicine, Fukui Medical University in March 2003 and received a Ph.D. from Tokyo Medical and Dental University in March 2007. He served as an Assistant Professor at the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, from April 2007 to March 2013, and as a Visiting Associate Professor/Research Scholar at the Masonic Cancer Center, University of Minnesota, from October 2013 to September 2016. His research interests include the Microenvironment of bone marrow, Pathology of bone marrow, Oncogene, Drug resistance, and CRISPR screening. CRISPR screening is a powerful tool to clarify the new mechanisms of drug resistance. Comprehensive screening is one promising approach for identifying new oncogenic targets for cancer cell survival.
Dr. Morito Kurata is currently an Associate Professor at the Division of Integrated Facilities, Pathology of Tokyo Medical and Dental University, Japan. He graduated from the Faculty of Medicine, Fukui Medical University in March 2003 and received a Ph.D. from Tokyo Medical and Dental University in March 2007. He served as an Assistant Professor at the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, from April 2007 to March 2013, and as a Visiting Associate Professor/Research Scholar at the Masonic Cancer Center, University of Minnesota, from October 2013 to September 2016. His research interests include the Microenvironment of bone marrow, Pathology of bone marrow, Oncogene, Drug resistance, and CRISPR screening. CRISPR screening is a powerful tool to clarify the new mechanisms of drug resistance. Comprehensive screening is one promising approach for identifying new oncogenic targets for cancer cell survival.